Antibacterial agent 341
Antibacterial agent 341 is an anti-bacterial agent. Antibacterial agent 341 shows broad-spectrum Gram-positive antibacterial activity. Antibacterial agent 341 targets phosphatidylglycerol (PG) and cardiolipin (CL) in bacterial cell membranes, induces sustained depolarization of membranes, and disrupts the cell membrane integrity. Antibacterial agent 341 exhibits anti-infection activity against S. aureus-induced subcutaneous abscesses in mice.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3023862-30-5
- Formule: C38H56N2O4
- Masse moléculaire:604.86
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
In Vitro
Antibacterial agent 341 (Compound I-9)(two-fold serial dilutions; 16-18 h) exhibits Gram-positive-selective antibacterial activity, potently inhibiting S. aureus with an MIC of 2 μg/mL and demonstrating broad-spectrum activity against clinically relevant Gram-positive pathogens[1].
Antibacterial agent 341 (1 h) has extremely low hemolytic toxicity against sheep red blood cells, with an HC50 >1280 μg/mL[1].
Antibacterial agent 341 (8 μg/mL; 8 h) rapidly kills S. aureus, eliminating all detectable bacteria within 2 h[1].
Antibacterial agent 341 (8-32 μg/mL; 22 min) induces rapid, sustained depolarization of S. aureus cell membrane, confirming its membrane-targeted mechanism of action[1].
Antibacterial agent 341 (16 μg/mL; 2 h) induces significant nucleic acid leakage from S. aureus cells, indicating potent membrane-disrupting activity[1].
Antibacterial agent 341 (8-16 μg/mL; 20 min) disrupts the cell membrane integrity of S. aureus, allowing PI to enter and label bacterial nucleic acids[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:S. aureus
-
Concentration:8, 16 μg/mL
-
Incubation Time:20 min
-
Result:Increased intracellular PI fluorescence intensity.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice with Staphylococcus aureus infection (female, 6-8 weeks old, 29-33 g, subcutaneous abscess model)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:s.c.; single injection
-
Result:Reduced bacterial survival rate in skin lesions to 0.485% at 5 mg/kg.
Reduced bacterial survival rate in skin lesions to 0.156% at 10 mg/kg.
Showed superior efficacy to 5 mg/kg vancomycin (HY-B0671) (bacterial survival rate 2.559%) at 5 mg/kg.
Markedly alleviated abscess symptoms, with only mild abscess formation observed at both doses.
Chemical Information
-
CAS No. 3023862-30-5
-
Masse moléculaire 604.86
-
Formule C38H56N2O4
-
SMILES
O=C(C1=CC=C(OCCCCCCCCCCOC2=CC=C(C(CCN3CCCCC3)=O)C=C2)C=C1)CCN4CCCCC4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)